LifeMine Therapeutics

LifeMine Therapeutics is a biotechnology startup based in the United States, founded in 2016. The company's slogan, "Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology," encapsulates its innovative approach to drug discovery. Leveraging proprietary genomic drug discovery platform, LifeMine is revolutionizing the field by mining genetically-encoded small molecules (GEMs) from the biosphere, aiming to bring speed, predictability, and scalability to small molecule drug discovery. Founded by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., along with entrepreneur/company-builder WeiQing Zhou, LifeMine focuses on uncovering potentially impactful drug candidates in the genomic space, particularly targeting oncology and immune modulation. In an impressive milestone, the company successfully secured a $175.00M Series C investment on 23 March 2022. Noteworthy investors in this round include Arch Venture Partners, GV, Invus, Blue Pool Capital, Fidelity, GlaxoSmithKline, MRL Ventures Fund, and 3W Partners. LifeMine's cutting-edge approach to drug discovery, experienced leadership, and strong investor backing position it as a promising player in the biotech landscape.